Palliative management of fatigue at the close of life: "It feels like my body is just worn out"

JAMA

Volumn 297, Issue 3, 2007, Pages 295-304

  Yennurajalingam, Sriram ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; ALENDRONIC ACID; ANTIHISTAMINIC AGENT; CARNITINE; DEXAMETHASONE; FLUOXETINE; ISOSORBIDE; LISINOPRIL; MEGESTROL ACETATE; METHYLPHENIDATE; METHYLPREDNISOLONE; MODAFINIL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OPIATE; SERTRALINE;

ABNORMAL BEHAVIOR; ADRENAL INSUFFICIENCY; AGITATION; ANAMNESIS; ANXIETY; APPETITE; BLEEDING; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIARRHEA; DIZZINESS; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DYSPEPSIA; EDEMA; FATIGUE; GASTRITIS; GLUCOSE BLOOD LEVEL; HALLUCINATION; HEADACHE; HEART ARRHYTHMIA; HICCUP; HIRSUTISM; HOT FLUSH; HUMAN; HYPERTENSION; IMPOTENCE; INFECTION; INSOMNIA; LABORATORY TEST; LIFESPAN; LUNG EMBOLISM; MOOD CHANGE; MUSCLE WEAKNESS; MYALGIA; NAUSEA; NERVOUSNESS; NEUROTOXICITY; ODOR; PALLIATIVE THERAPY; PATHOGENESIS; PHYSICAL EXAMINATION; PREVALENCE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RESTLESSNESS; REVIEW; RHINITIS; SEIZURE; SIDE EFFECT; SLURRED SPEECH; SWEATING; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THRUSH; VALIDITY; VOMITING; WEIGHT GAIN; WOUND HEALING;

EID: 33846449537     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.297.3.295     Document Type: Review

References (113)

1. Sharpe MC, Archnard LC, Banatvala JE. A report - chronic fatigue syndrome, guidelines for research. J R Soc Med. 1991;84:118-121.
2. National Comprehensive Cancer Network Practice Guidelines. Cancer-Related Fatigue Panel 2006 Guidelines. Rockledge, Pa: National Comprehensive Cancer Network; March 2006. http://www.nccn.org. Accessed September 2006.
3. Cella D, Peterman A, Passik S, et al. Progress towards guidelines for the management of fatigue. Oncology. 1998;12:369-377.
4. Portenoy RK, Itri L. Cancer-related fatigue. Oncologist. 1999;4:1-10.
5. Working Group of the Royal Australasian College of Physicians. Chronic fatigue syndrome. Med J Aust. 2002;176(suppl):S23-S56.
6. Jason LA, Jordan KM, Richman JA, et al. A community-based study of prolonged fatigue and chronic fatigue. J Health Psychol. 1999;4:9-26.
7. Krupp LB. Fatigue in multiple sclerosis. CNS Drugs. 2003;17:225-234.
8. Wysenbeek AJ, Leibovici L, Weinberger A, Guedj D. Fatigue in systemic lupus erythematosus. Br J Rheumatol. 1993;32:633-635.
9. Walke LM, Gallo WT, Tinetti ME, Fried TR. The burden of symptoms among community-dwelling older persons with advanced chronic disease. Arch Intern Med. 2004;164:2321-2324.
10. Wolfe F, Hawley DJ, Wilson K. The prevalence and meaning of fatigue in rheumatic disease. J Rheumatol. 1996;23:1407-1417.
11. Cardenas DD, Kutner NG. The problem of fatigue in dialysis patients. Nephron. 1982;30:336-340.
12. Cella D, Davis K, Breitbart W, Curt G; Fatigue Coalition. Cancer-related fatigue. J Clin Oncol. 2001;19:3385-3391.
13. Lawrence DP, Kupelnick B, Miller K, et al. Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr. 2004;32:40-50.
14. Stone P, Richards M, A'Hern R, Hardy J. A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol. 2000;11:561-567.
15. Smets EM, Garssen B, Schuster-Uitterhoeve AL, et al. Fatigue in cancer patients. Br J Cancer. 1993;68:220-224.
16. Glaus A, Crow R, Hammond S. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Support Care Cancer. 1996;4:82-96.
17. Liao S, Ferrell BA. Fatigue in an older population. J Am Geriatr Soc. 2000;48:426-430.
18. Lee BN, Dantzer R, Langley K, et al. A cytokine-based neuroimmunologic mechanism of cancer-related symptom. Neuroimmunomodulation. 2004;11:279-292.
19. Hamerman D, Berman JW, Albers GW, et al. Emerging evidence for inflammation in conditions frequently affecting older adults. J Am Geriatr Soc. 1999;47:1016-1025.
20. Ooi WL, Barrett S, Hossain M, et al. Patterns of orthostatic blood pressure change and their clinical correlates in a frail, elderly population. JAMA. 1997;277:1299-1304.
21. Michalaki V, Syrigos K, Charles P, et al. Serum levels of IL-6 and TNF-α correlate with clinicopathological features and patient survival in patients with prostate cancer. Br J Cancer. 2004;90:2312-2316.
22. Moss RB, Mercandetti A, Vojdani A. TNF-α and chronic fatigue syndrome. J Clin Immunol. 1999;19:314-316.
23. Adler HL, McCurdy MA, Kattan MW, et al. Elevated levels of circulating interleukin-6 and transforming growth factor-β1 in patients with metastatic prostatic carcinoma. J Urol. 1999;161:182-187.
24. Smets EMA, Garssen B, Bonke B, de Haes JC. The Multidimensional Fatigue Inventory. J Psychosom Res. 1995;39:315-325.
25. Dittner AJ, Wessely SC, Brown RG. The assessment of fatigue. J Psychosom Res. 2004;56:157-170.
26. Belza B, Steele BG, Hunziker J, Lakshminaryan S, Holt L, Buchner DM. Correlates of physical activity in chronic obstructive pulmonary disease. Nurs Res. 2001;50:195-202.
27. Stein KD, Martin SC, Hann DM, Jacobsen PB. A multidimensional measure of fatigue for use with cancer patients. Cancer Pract. 1998;6:143-152.
28. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The Revised Piper Fatigue Scale. Oncol Nurs Forum. 1998;25:677-684.
29. Schwartz A, Meek P. Additional construct validity of the Schwartz Cancer Fatigue Scale. J Nurs Meas. 1999;7:35-45.
30. Mendoza TR, Wang XS, Cleeland CS, et al. The rapid assessment of fatigue severity in cancer patients. Cancer. 1999;85:1186-1196.
31. Hann DM, Jacobsen PB, Azzarello LM, et al. Measurement of fatigue in cancer patients. Qual Life Res. 1998;7:301-310.
32. Cella D. Manual of the Functional Assessment of Chronic illness Therapy (FACIT) Measurement System. Evanston, Ill: Center on Outcomes, Research and Education (CORE); 1997.
33. Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS). J Palliat Care. 1991;7:6-9.
34. Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer. 2000;88:2164-2171.
35. Ware JE, Sherbourne CD. The MOS 36-item short-form health survey (SF-36), I. Med Care. 1992;30:473-483.
36. Respini D, Jacobsen PB, Thors C, Tralongo P, Balducci L. The prevalence and correlates of fatigue in older cancer patients. Crit Rev Oncol Hematol. 2003;47:273-279.
37. Prue G, Rankin J, Allen J, Gracey J, Cramp F. Cancer-related fatigue. Eur J Cancer. 2006;42:846-863.
38. Murtagh J. Fatigue - a general diagnostic approach. Aust Fam Physician. 2003;32:873-876.
39. Fishbain DA, Cole B, Cutler RB, Lewis J, Rosomoff HL, Rosomoff R. Is pain fatiguing? Pain Med. 2003;4:51-62.
40. Somogyi-Zalud E, Zhong Z, Lynn J, Hamel MB. Elderly persons' last six months of life. J Am Geriatr Soc. 2000;48(5 suppl):S131-S139.
41. Lawlor PG. The panorama of opioid-related cognitive dysfunction in patients with cancer. Cancer. 2002;94:1836-1853.
42. Inouye SK, van Dyck CH, Alessi CA, Balkin S, Siegal AP, Horwitz RI. Clarifying confusion. Ann Intern Med. 1990;113:941-948.
43. Breitbart W, Rosenfeld B, Roth A, Smith MJ, Cohen K, Passik S. The Memorial Delirium Assessment Scale. J Pain Symptom Manage. 1997;13:128-137.
44. Morrison RS, Magaziner J, Gilbert M, et al. Relationship between pain and opioid analgesics on the development of delirium following hip fracture. J Gerontol A Biol Sci Med Sci. 2003;58:76-81.
45. Block SD. Psychological issues in end-of-life care. J Palliat Med. 2006;9:751-772.
46. Lander M, Wilson K, Chochinov HM. Depression and the dying older patient. Clin Geriatr Med. 2000;16:335-356.
47. Lawlor PG, Gagnon B, Mancini IL, et al. Occurrence, causes, and outcome of delirium in patients with advanced cancer. Arch Intern Med. 2000;160:786-794.
48. Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer. 2005;104:788-793.
49. Johnson SK, DeLuca J, Natelson BH. Chronic fatigue syndrome. Ann Behav Med. 1999;21:258-271.
50. Valentine AD, Meyers CA, Kling MA, et al. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998;25(suppl 1):39-47.
51. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in patients with terminal cancer. Cancer. 1997;79:835-842.
52. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am. 2002;16:589-617.
53. Coats AJ. Origin of symptoms in patients with cachexia with special reference to weakness and shortness of breath. Int J Cardiol. 2002;85:133-139.
54. Gutstein HB. The biologic basis of fatigue. Cancer. 2001;92(6 suppl):1678-1683.
55. Reife CM. Involuntary weight loss. Med Clin North Am. 1995;79:299-313.
56. Morley JE, Thomas DR. Anorexia and aging. Nutrition. 1999;15:499-503.
57. Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States. Blood. 2004;104:2263-2268.
58. Zakai NA, Katz R, Hirsch C, et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort. Arch Intern Med. 2005;165:2214-2220.
59. Penninx BW, Guralnik JM, Onder G, et al. Anemia and decline in physical performance among older persons. Am J Med. 2003;115:104-110.
60. Dunst J. Hemoglobin level and anemia in radiation oncology. Semin Oncol. 2000;27(suppl 4):4-17.
61. Nemeth E, Rivera S, Gabayan V, et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest. 2004;113:1271-1276.
62. Rockey DC, Cello JP. Evaluation of the gastrointestinal tract in patients with iron-deficiency anemia. N Engl J Med. 1993;329:1691-1695.
63. Bruera E, Roca E, Cedaro L, Carraro S, Chacon R. Action of oral methylprednisolone in terminal cancer patients. Cancer Treat Rep. 1985;69:751-754.
64. Della Cuna GR, Pellegrini A, Piazzi M. Effect of methylprednisolone sodium succinate on quality of life in preterminal cancer patients. Eur J Cancer Clin Oncol. 1989;25:1817-1821.
65. Popiela T, Lucchi R, Giongo F; The Methylprednisolone Female Preterminal Cancer Study Group. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer. 1989;25:1823-1829.
66. Moertel CG, Schutt A, Reitemeir RJ, Hahn RG. Corticosteroid therapy in preterminal gastro-intestinal cancer. Cancer. 1974;33:1607-1609.
67. Inoue A, Yamada Y, Matsumura Y, et al. Randomized study of dexamethasone treatment for delayed emesis, anorexia and fatigue induced by irinotecan. Support Care Cancer. 2003;11:528-532.
68. Hardy JR, Rees E, Ling J, et al. A prospective survey of the use of dexamethasone on a palliative care unit. Palliat Med. 2001;15:3-8.
69. Bruera E, Driver L, Barnes EA, et al. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer. J Clin Oncol. 2003;21:4439-4443.
70. Bruera E, Valero V, Driver L, et al. Patient-controlled methylphenidate for cancer fatigue. J Clin Oncol. 2006;24:2073-2078.
71. Bruera E, Ernst S, Hagen N, et al. Effectiveness of megestrol acetate in patients with advanced cancer. Cancer Prev Control. 1998;2:74-78.
72. Rammohan KW, Rosenberg JH, Lynn DJ, Blumenfeld AM, Pollak CP, Nagaraja HN. Efficacy and safety of modafinil (Provigil) for the treatment of fatigue in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2002;72:179-183.
73. Plioplys AV, Plioplys S. Amantadine and L-carnitine treatment of chronic fatigue syndrome. Neuropsychobiology. 1997;35:16-23.
74. Tomassini V, Pozzilli C, Onesti E, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis. J Neurol Sci. 2004;218:103-108.
75. Fishbain DA, Lewis J, Cole B, et al. Multidisciplinary pain facility treatment outcome for pain-associated fatigue. Pain Med. 2005;6:299-304.
76. Bruera E, Miller MJ, MacMillan K, et al. Neuropsychological effect of methylphenidate in patients receiving a continuous infusion of narcotics for cancer pain. Pain. 1992;48:163-166.
77. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed elderly patients. Am J Geriatr Psychiatry. 2005;13:884-891.
78. Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. Am J Hosp Palliat Care. 2001;18:403-407.
79. Tisdale MJ. Cancer cachexia. Nutrition. 1997;13:1-7.
80. Yavuzsen T, Davis MP, Walsh D, LeGrande S, Lagman R. Systematic review of the treatment of cancer-associated anorexia and weight loss. J Clin Oncol. 2005;23:8500-8511.
81. Bruera E, Belzile M, Neumann C, Harsanyi Z, Babul N, Darke A. A double-blind, crossover study of controlled-release metoclopramide and placebo for the chronic nausea and dyspepsia of advanced cancer. J Pain Symptom Manage. 2000;19:427-435.
82. Reyes-Teran G, Sierra-Madero JG, Martinez del Cerro V, et al. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial. AIDS. 1996;10:1501-1507.
83. Wigmore SJ, Barber MD, Ross JA, Tisdale MJ, Fearon KC. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr Cancer. 2000;36:177-184.
84. Berman RS, Harrison LE, Pearlstone DB, Burt M, Brennan MF. Growth hormone, alone and in combination with insulin, increases whole body and skeletal muscle protein kinetics in cancer patients after surgery. Ann Surg. 1999;229:1-10.
85. Coodley GO, Coodley MK. A trial of testosterone therapy for HIV-associated weight loss. AIDS. 1997;11:1347-1352.
86. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97.
87. Lissoni P, Paolorossi F, Tancini G, et al. Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer. 1996;32A:1340-1343.
88. Agteresch HJ, Dagnelie PC, van der Gaast A, Stijnen T, Wilson JH. Randomized clinical trial of adenosine 5′-triphosphate in patients with advanced non-small-cell lung cancer. J Natl Cancer Inst. 2000;92:321-328.
89. MacDonald N, Easson AM, Mazurak VC, et al. Understanding and managing cancer cachexia. J Am Coll Surg. 2003;197:143-161.
90. Armitage JO. Management of anemia in patients with cancer. Clin Oncol Updates. 1998;1:1-12.
91. Drueke TB, Locatelli F, Clyne N. Normalization of hemoglobin level in patient with chronic kidney disease and anemia. N Engl J Med. 2006;355:2071-2084.
92. Eisenstaedt R, Penninx BW, Woodman RC. Anemia in the elderly. Blood Rev. 2006;20:213-226.
93. Demetri GD, Kris M, Wade J, Degos L, Cella D. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumour type. J Clin Oncol. 1998;16:3412-3425.
94. Osterborg A, Brandberg Y, Molostova V, et al. Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol. 2002;20:2486-2494.
95. Shasha D, George MJ, Harrison LB. Once-weekly dosing of epoetin-alpha increases hemoglobin and improves quality of life in anemic cancer patients receiving radiation therapy either concomitantly or sequentially with chemotherapy. Cancer. 2003;98:1072-1079.
96. Conill C, Verger E, Henriquez I, et al. Symptom prevalence in the last week of life. J Pain Symptom Manage. 1997;14:328-331.
97. Munch TN, Zhang T, Willey J, Palmer JL, Bruera E. The association between anemia and fatigue in patients with advanced cancer receiving palliative care. J Palliat Med. 2005;8:1144-1149.
98. Ream E, Richardson A. Fatigue: a concept analysis. Int J Nurs Stud. 1996;33:519-529.
99. Winningham ML. Strategies for managing cancer-related fatigue syndrome. Cancer. 2001;92(4 suppl):988-997.
100. Dimeo FC, Stieglitz RD, Novelli-Fischer U, et al. Effects of physical activity on the fatigue and psychologic status of cancer patients during chemotherapy. Cancer. 1999;85:2273-2277.
101. Mock V, Pickett M, Ropka M, et al. Fatigue and quality of life outcomes of exercise during cancer treatment. Cancer Pract. 2001;9:119-127.
102. Courneya KS, Mackey JR, Bell GJ, et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors. J Clin Oncol. 2003;21:1660-1668.
103. Segal RJ, Reid RD, Courneya KS, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21:1653-1659.
104. Mock V, Frangakis C, Davidson NE, et al. Exercise manages fatigue during breast cancer treatment. Psychooncology. 2005;14:464-477.
105. Schwartz AL, Thompson JA, Masood N. Interferon-induced fatigue in patients with melanoma. Oncol Nurs Forum. 2002;29:E85-E90.
106. Oldervoll LM, Loge JH, Paltiel H, et al. The effect of a physical exercise program in palliative care. J Pain Symptom Manage. 2006;31:421-430.
107. MacVicar MG, Winningham ML. Promoting the functional capacity of cancer patients. Cancer Bull. 1986;385:235-239.
108. Jenkins CA, Scarfe A, Bruera E. Integration of palliative care with alternative medicine in patients who have refused curative cancer therapy. J Palliat Care. 1998;14:55-59.
109. Jenkins C, Bruera E. Assessment and management of medically ill patients who refuse life-prolonging treatments. J Palliat Care. 1998;14:18-24.
110. Slatkin NE, Rhiner M. Treatment of opiate-related sedation. J Support Oncol. 2003;1:53-63.
111. Bruera E, Strasser F, Shen L, et al. The effect of donepezil on sedation and other symptoms in patients receiving opioids for cancer pain. J Pain Symptom Manage. 2003;26:1049-1054.
112. Calman KC. Quality of life in cancer patients-an hypothesis. J Med Ethics. 1984;10:124-127.
113. Neuenschwander H, Bruera E, Cavalli F. Matching the clinical function and symptom status with the expectations of patients with advanced cancer, their families, and health care workers. Support Care Cancer. 1997;5:252-256.